Most material SEC filings — November 2, 2026

INOVIO received FDA accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a plasmid DNA immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP). The approval is based on RRP-001 trial data (n=32 patients): 7 of 26 efficacy-evaluable patients (27%) achieved complete response (no surgeries required in 12 months post-treatment) versus median 4.5 pre-treatment surgeries annually. VOCERYQ will launch Q1 2027 with availability to order/ship in ~60 days; INOVIO estimates 25,000+ RRP patients in U.S. market. Continued approval contingent on confirmatory study protocol due end-2026, finalized mid-2027.

LS Power Equity Advisors, which owns ~178M shares (56% voting control) of EVgo, submitted a non-binding proposal on November 2, 2026 to acquire all remaining public shares at $2.00/share cash—a 62% premium to 30-day VWAP and 59% premium to closing price as of October 30, 2026. The proposal requires recommendation by a special committee of independent directors and contemplates a long-form merger structure.

AAR Corp is offering $955M of senior notes due 2031 and $960M due 2034 (totaling $1.915B) to finance its acquisition of a 65% controlling stake in MRO Holdings, Inc. at an implied enterprise value of ~$4.0B. Financing sources include the debt offering, $231.6M from a PIPE equity placement (2.2M shares at $104.50), ~$230M revolving credit draw, and ~$780.8M in Series A Preferred Stock issuance. MRO Holdings generated $943.7M revenue and $291.4M Adjusted EBITDA in the twelve months ended June 30, 2026; it carries $1.389B total debt. Proceeds will also refinance MRO's existing $1.389B debt and cover transaction costs (~$53M).

U.S. GoldMining reported that on September 25, 2026, the U.S. Army Corps of Engineers issued a Public Notice for the Alaska Industrial Development and Export Authority's permit application for the 78.5-mile West Susitna Access Project (WSAP) under Clean Water Act Section 404, with the comment period now closed and USACE conducting evaluation. The USACE designated the WSAP as a critical mineral project and determined it qualifies for emergency permitting procedures under Executive Order 14156, expected to reduce normal processing time. Additionally, the Port MacKenzie rail extension received a $249M U.S. Department of Transportation award with $34M in AIDEA matching funds, and neighboring Nova Minerals secured final mining permits for its antimony project in approximately three months, demonstrating regional permitting momentum.

Lumentum reported Q1 FY2027 net revenue of $1,262.6M (up 136.5% YoY from $533.8M), with GAAP net income of $360.3M ($3.54 diluted EPS) and non-GAAP net income of $461.1M ($4.57 diluted EPS). The company secured its second major NPO/CPO (network processor optical/co-processor optical) customer win with purchase commitments exceeding $5 billion. Q2 FY2027 guidance: revenue $1.575–$1.625B, non-GAAP operating margin 45–46%, non-GAAP diluted EPS $5.90–$6.20.

uniQure announced FDA acceptance of its BLA for ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington's disease, under Accelerated Approval pathway with Priority Review. FDA set PDUFA target action date of May 1, 2027. If approved, it would be the first disease-modifying treatment for Huntington's disease. The BLA is supported by 36-month Phase I/II data (51 patients dosed total); confirmatory trial (~200 patients, 2:1 randomized design) screening to begin by end of 2026.

Cipher Digital amended its Barber Lake data center lease with a leading AI lab, extending the term by 10 years (to 20 years total) and increasing total contracted revenue to $9.1 billion—adding ~$5.2 billion of incremental rent. The company also recognized first HPC lease revenue ($5.9M in Q3 2026), received conditional ERCOT base load classification for 1 GW at Colchis, began developing lateral pipelines for up to 2.5 GW on-site generation, and issued $850M of 0.000% convertible notes due 2032 to fund the expansion while equitizing $165.9M of 2030 convertible notes.

CorMedix reported $355M cash on hand (Sept 30, 2026) and reaffirmed full-year 2026 revenue guidance of $325–$345M. CMS finalized the 2027 ESRD PPS rule on October 28, 2026, setting DefenCath's post-TDAPA Add-on at $8.32 per dialysis session for Q1 2027 (3.5× the current $2.37 rate). CorMedix projects the Add-on will decline in Q2 2027 but rise in Q3/Q4, with all four quarters exceeding $2.37 and an annual average above 2× the current rate, subject to CMS utilization methodology.

Intrusion Inc. exchanged $4.0M in partitioned secured promissory notes held by Streeterville Capital, LLC for 4,000 shares of newly designated Series B Preferred Stock (3,250 shares for $3.25M of Note #1; 750 shares for $750K of Note #2), effective October 29, 2026. The Series B stock carries a 10% annual preferred return, 2.5%-5% quarterly dividends, liquidation preference senior to common stock, and grants the holder (Streeterville) extensive protective covenants including consent rights over capital issuances, asset dispositions, and fundamental transactions. The remaining unpaid balance on the original notes ($704.4K on Note #1; $884.3K on Note #2) continues unchanged.

Allarity Therapeutics resolved a $4.9M aggregate liability owed to Novartis Pharma AG under a prior license agreement by paying $1M as full settlement on October 28, 2026. The agreement grants mutual releases of all claims between the parties. Separately, Allarity announced its first commercial CLIA laboratory services contract with a European biotech company, expected to generate development/validation fees and potential recurring revenue.

Lazard completed its acquisition of Campbell Lutyens on November 1, 2026, announced April 30, 2026. Upfront consideration paid primarily in Lazard stock with lock-up arrangements up to 3 years. Combined entity (Lazard CL) brings ~300 advisory professionals across 19 offices; expected ~$500M combined revenue in 2027, accretive to earnings before synergies. Transaction creates integrated private capital advisory platform advising on $1T+ primary capital raised and secondaries volume historically.

Alpine Income Property Trust closed acquisition of 13-property industrial portfolio for $117.3 million ($63/sq ft), totaling 1.9M sq ft across 11 states. Portfolio is 100% leased to nine tenants under triple-net leases with 10.2 years weighted-average remaining lease term and annual rent escalators. Acquisition funded through revolving credit facility borrowings.

Tempus AI reported Q3 2026 revenue of $411.5M (23% YoY growth), with oncology volume up 32% and Data Applications revenue up 33%. The company raised full-year 2026 revenue guidance to $1.60–$1.605B (~25% growth) and expects ~$65M Adjusted EBITDA. Major developments: (1) Strategic collaboration with Merck and Moderna for neoantigen therapy commercialization; (2) BMS data licensing deal worth $137.5M over 5 years for oncology data plus $55M for Alzheimer's/dementia data; (3) Personalis acquisition regulatory clearance granted (shareholder vote Nov 30, 2026); (4) Two FDA 510(k) clearances for cardiology products. Cash position: $854.4M.

Seaport reported Q3 2026 results with $403.8M in cash/investments (91% of total assets) expected to fund operations into 2029. Key clinical milestones: GlyphAllo Phase 1 driving trial met primary endpoint (375mg did not impair next-morning driving vs placebo); first patient dosed in GlyphAgo Phase 2a GAD trial with Phase 2/3 initiation planned 1H 2027; BUOY-1 Phase 2b MDD trial enrollment on track with topline data expected 1H 2027. Q3 R&D expenses increased $3.4M to $23.9M; net loss widened to $26.4M vs $22.5M prior year.

Q3 2026 net product revenue was $259.7M (52% YoY growth): AUVELITY $207.6M (+53% YoY), SUNOSI $48.2M (+47% YoY), SYMBRAVO $3.9M (+88% YoY). Net loss improved to $12.9M ($0.25/share) vs. $47.2M loss prior year. Cash balance $313.9M; company states it can fund operations to cash flow positivity. Initiated SUMMIT Phase 3 trial for AXS-05 in smoking cessation; multiple pipeline milestones anticipated through 2027.

Lightbridge was selected in August 2026 for the DOE Nuclear Energy Launch Pad INL program, providing an accelerated pathway to build a Pilot Factory at Idaho National Laboratory to manufacture lead test assemblies. The company also entered into a loop irradiation testing agreement (PTS No. 2) with Battelle Energy Alliance in August 2026. However, net loss for nine months ended September 30, 2026 was $20.4M (vs. $12.4M prior year); R&D spending nearly tripled to $12.6M (vs. $5.3M); operating cash burn was $13.2M. Cash position improved to $236.7M (from $201.9M year-end 2025) via 4.3M shares sold under ATM program for $48.9M net proceeds. Working capital: $234.2M.

Iron Horse Acquisition II Corp. (SPAC, $234M assets) is merging with ELECTRA AI, a battery management software company, at a $250.3M pre-money equity valuation ($10/share). At close, ELECTRA AI shareholders will own 65.8% of the combined ~38M-share entity (pro forma enterprise value ~$353M after $27.6M net cash). No dollar amount, customer names, or concrete revenue figures disclosed for ELECTRA AI; filing shows pipeline claims (5.3 TWh non-binding discussions, 1 GWh under management, 70%+ projected contribution margins) but no audited financials, revenue, or near-term earnings guidance provided.

Estée Lauder reported Q1 FY2027 net sales of $3.715B (+7% reported, +6% organic YoY) with gross margin expanding 230bps to 75.7% and operating income surging 100%+ to $408M. Diluted EPS reached $0.64 vs $0.13 prior year. The company raised FY2027 guidance: organic sales growth to 4.0%-5.5% (from 3%-5%), adjusted operating margin to 12.9%-13.7% (from 12.7%-13.5%), and adjusted EPS to $3.20-$3.45 (from $3.10-$3.35). Growth was broad-based across categories (Fragrance +20%, Skin Care +4%) and regions, with particular strength in Asia/Pacific (+10% organic) and Mainland China (+9% organic).